Siglec-7 Antibody (F-2): sc-398181

Siglec-7 Antibody (F-2) is a mouse monoclonal IgG1 antibody that detects Siglec-7 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Siglec-7 is a member of the sialic acid-binding immunoglobulin superfamily and plays a crucial role in modulating immune responses, particularly in the inhibition of natural killer (NK) cell cytotoxicity. This function is vital for maintaining immune homeostasis and preventing excessive tissue damage during immune responses. Siglec-7 is predominantly expressed in monocytes and resident blood cells, but expression is notably absent in parenchymatous cells, highlighting a specialized role in immune regulation. The interaction of Siglec-7 with sialylated ligands on target cells can lead to the downregulation of NK cell activity, which is essential for controlling immune responses against tumors and viral infections. The ability of Siglec-7 to mediate these interactions underscores importance in both innate and adaptive immunity, making Siglec-7 a significant target for research in immunology and therapeutic interventions. Anti-Siglec-7 antibody (F-2) is an invaluable tool for researchers aiming to explore the complex mechanisms of immune regulation and the potential therapeutic applications of modulating Siglec-7 activity.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Siglec-7 Antibody (F-2) References:

1. Siglec-7 tetramers characterize B-cell subpopulations and leukemic blasts.  |  Gieseke, F., et al. 2012. Eur J Immunol. 42: 2176-86. PMID: 22585296
2. Siglec-7 as a Novel Biomarker to Predict Mortality in Decompensated Cirrhosis and Acute Kidney Injury.  |  Allegretti, AS., et al. 2016. Dig Dis Sci. 61: 3609-3620. PMID: 27655105
3. DNA methylation-mediated Siglec-7 regulation in natural killer cells via two 5' promoter CpG sites.  |  Huang, HT., et al. 2020. Immunology. 160: 38-51. PMID: 32027025
4. Reduced Siglec-7 expression on NK cells predicts NK cell dysfunction in primary hepatocellular carcinoma.  |  Tao, L., et al. 2020. Clin Exp Immunol. 201: 161-170. PMID: 32319079
5. Identification and functional characterization of a Siglec-7 counter-receptor on K562 cells.  |  Yoshimura, A., et al. 2021. J Biol Chem. 296: 100477. PMID: 33640457
6. Molecular Basis and Role of Siglec-7 Ligand Expression on Chronic Lymphocytic Leukemia B Cells.  |  Chang, LY., et al. 2022. Front Immunol. 13: 840388. PMID: 35711441
7. Histone deacetylation-regulated cell surface Siglec-7 expression promoted megakaryocytic maturation and enhanced platelet-like particle release.  |  Huang, YF., et al. 2023. J Thromb Haemost. 21: 329-343. PMID: 36700509
8. Tumor cell-intrinsic and tumor microenvironmental conditions co-determine signaling by the glycoimmune checkpoint receptor Siglec-7.  |  van Houtum, EJH., et al. 2023. Cell Mol Life Sci. 80: 169. PMID: 37253806
9. Synthesis and Binding Mode Predictions of Novel Siglec-7 Ligands.  |  Frank, M., et al. 2023. J Med Chem. 66: 14315-14334. PMID: 37793071
10. Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer.  |  Wen, RM., et al. 2024. J Clin Invest. 134: PMID: 39436703

The preferred Siglec-7 antibody is Siglec-7 Antibody (A-7): sc-398919.